MAPK3 and neoplasm: In contrast, in both AP20187-treated DCIS-iFGFR1 and TNFAIP3 xenograft tumors, p-ERK1/2 immunostaining signals were detected in almost all of the tumor cells at stronger levels (Fig. 7d).